Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Equivalents: 2017-2021

Historic Cash & Equivalents for Cogent Biosciences (COGT) over the last 4 years, with Sep 2021 value amounting to $202.9 million.

  • Cogent Biosciences' Cash & Equivalents rose 56.77% to $202.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $202.9 million, marking a year-over-year increase of 56.77%. This contributed to the annual value of $242.2 million for FY2020, which is 547.15% up from last year.
  • As of Q3 2021, Cogent Biosciences' Cash & Equivalents stood at $202.9 million, which was down 6.98% from $218.1 million recorded in Q2 2021.
  • In the past 5 years, Cogent Biosciences' Cash & Equivalents ranged from a high of $242.2 million in Q4 2020 and a low of $21.3 million during Q2 2020.
  • Its 3-year average for Cash & Equivalents is $115.7 million, with a median of $59.1 million in 2019.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 61.80% in 2020, then soared by 921.95% in 2021.
  • Over the past 5 years, Cogent Biosciences' Cash & Equivalents (Quarterly) stood at $36.9 million in 2017, then spiked by 103.39% to $75.0 million in 2018, then tumbled by 50.12% to $37.4 million in 2019, then spiked by 547.15% to $242.2 million in 2020, then spiked by 56.77% to $202.9 million in 2021.
  • Its last three reported values are $202.9 million in Q3 2021, $218.1 million for Q2 2021, and $230.7 million during Q1 2021.